{"protocolSection":{"identificationModule":{"nctId":"NCT03170609","orgStudyIdInfo":{"id":"C1091001"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age","officialTitle":"A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE"},"statusModule":{"statusVerifiedDate":"2019-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-06-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-06-25","type":"ACTUAL"},"completionDateStruct":{"date":"2018-06-25","type":"ACTUAL"},"studyFirstSubmitDate":"2017-05-26","studyFirstSubmitQcDate":"2017-05-26","studyFirstPostDateStruct":{"date":"2017-05-31","type":"ACTUAL"},"resultsFirstSubmitDate":"2019-06-13","resultsFirstSubmitQcDate":"2019-06-13","resultsFirstPostDateStruct":{"date":"2019-07-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-06-13","lastUpdatePostDateStruct":{"date":"2019-07-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine. Healthy adults aged 18 to 49 years of age with no history of group B streptococcal vaccination will be randomized to receive either a single intramuscular dose of multivalent group B streptococcus vaccine (various formulations at 3 dose levels) or a placebo (saline control)."},"conditionsModule":{"conditions":["Group B Streptococcal Infections"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":365,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Lowest dose formulation a","type":"EXPERIMENTAL","description":"Multivalent group B streptococcus vaccine","interventionNames":["Biological: Multivalent group B streptococcus vaccine"]},{"label":"Middle dose formulation a","type":"EXPERIMENTAL","description":"Multivalent group B streptococcus vaccine","interventionNames":["Biological: Multivalent group B streptococcus vaccine"]},{"label":"Highest dose formulation a","type":"EXPERIMENTAL","description":"Multivalent group B streptococcus vaccine","interventionNames":["Biological: Multivalent group B streptococcus vaccine"]},{"label":"Lowest dose formulation b","type":"EXPERIMENTAL","description":"Multivalent group B streptococcus vaccine","interventionNames":["Biological: Multivalent group B streptococcus vaccine"]},{"label":"Middle dose formulation b","type":"EXPERIMENTAL","description":"Multivalent group B streptococcus vaccine","interventionNames":["Biological: Multivalent group B streptococcus vaccine"]},{"label":"Highest dose formulation b","type":"EXPERIMENTAL","description":"Multivalent group B streptococcus vaccine","interventionNames":["Biological: Multivalent group B streptococcus vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Saline control","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Multivalent group B streptococcus vaccine","description":"Various formulations at three dose levels","armGroupLabels":["Highest dose formulation a","Highest dose formulation b","Lowest dose formulation a","Lowest dose formulation b","Middle dose formulation a","Middle dose formulation b"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Saline Control","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade","description":"Hemoglobin:Grade(G)1: 11-13.5g/dL, G2:9.5-12.4g/dL,G3:8-10.4 g/dL, G4:\\<8.0 g/dL; leukocyte increase:G1: 10.8-15\\*10\\^9/Liter\\[L\\],G2:\\>15-20\\*10\\^9/L, G3:\\>20-25\\*10\\^9/L, G4:\\>25\\*10\\^9/L,leukocyte decrease: G1: 2.5-3.5\\*10\\^9/L, G2: 1.5-\\<2.5\\*10\\^9/L, G3: 1-\\<1.5\\*10\\^9/L, G4:\\<1\\*10\\^9/L; neutrophil decrease:G1: 1.5-2\\*10\\^9/L, G2:1-\\<1.5\\*10\\^9/L, G3:0.5-\\<1\\*10\\^9/L,G4:\\<0.5\\*10\\^9/L; platelets:G1: 125-140\\*10\\^9/L, G2:100-124\\*10\\^9/L, G3:25-99\\*10\\^9/L, G4:\\<25\\*10\\^9/L; eosinophils: G1: 0.65-1.5\\*10\\^9/L, G2:\\>1.5-5\\*10\\^9/L, G3:\\>5\\*10\\^9/L, G4: hypereosinophilic;alanine aminotransferase,aspartate aminotransferase:G1: 1.1-2.5 \\*ULN, G2:2.6-5.0\\*ULN, G3:5.1-10\\*ULN, G4:\\>10\\*ULN; alkaline phosphatase:G1: 1.1-2\\*ULN, G2:2.1-3\\*ULN, G3:3.1-10\\*ULN, G4:\\>10\\*ULN; Bilirubin:G1: 1.1-1.5\\*ULN, G2: 1.26-2\\*ULN,G3: 1.51-3.0\\*ULN,G4:\\>1.75\\*ULN;blood urea nitrogen:G1:23-26mg/dL,G2:27-31mg/dL,G3:\\>31mg/dL, G4:dialysis;creatinine:G1:1.5-1.7mg/dL,G2:1.8-2mg/dL,G3:2.1-2.5 mg/dL,G4:dialysis.Categories with\\>=1 participant with abnormality are reported only.","timeFrame":"1 week after vaccination"},{"measure":"Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination","description":"Local reactions were collected by using an e-diary and included redness, swelling and pain at injection site. Redness and swelling were graded as: mild (2.5-5.0 centimeter \\[cm\\]), moderate (greater than \\[\\>\\] 5.0-10.0 cm) and severe (\\>10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis). Pain at injection site was graded as: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever \\>24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity which resulted in missed days of work or school or was otherwise incapacitating, or included use of narcotics for analgesia), and grade 4 (required emergency room visit or hospitalization). The maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.","timeFrame":"Within 14 days after vaccination"},{"measure":"Percentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination","description":"Fever:38.0-38.4 degree Celsius (C),38.5-38.9 degree C,39.0-40.0 degree C,\\>40.0 degree C;nausea/vomiting:mild(not interfered with activity/1-2times in 24 hours\\[hr\\]),moderate(some interference with activity/\\>2times in 24hr),severe(prevented daily activity;required intravenous hydration); diarrhea:mild(2-3 loose stools in 24hr),moderate(4-5 loose stools in 24hr),severe(\\>=6 loose stools in 24 hr); headache:mild(not interfered with activity),moderate(repeated use of non-narcotic pain reliever \\>24 hr/some interference with activity),severe(significant;any use of narcotic pain reliever/prevented daily activity);fatigue,muscle and joint pain:mild(not interfered with activity), moderate(some interference with activity),severe(significant;prevented daily activity).Prevented daily activity=missed days of work, school/otherwise incapacitating/use of narcotics for analgesia.Nausea/vomiting,diarrhea,headache,fatigue/tiredness,muscle and joint pain: grade 4=emergency room visit or hospitalization.","timeFrame":"Within 14 days after vaccination"},{"measure":"Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.","timeFrame":"Within 1 month after vaccination"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.","timeFrame":"Within 6 months after vaccination"},{"measure":"Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination","description":"An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.","timeFrame":"Within 6 months after vaccination"}],"secondaryOutcomes":[{"measure":"GBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination","description":"Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.","timeFrame":"1 month after vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy adults (male and female) 18 to 49 years of age at enrollment who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.\n2. Negative urine pregnancy test at Visit 1 for all female subjects who are of childbearing potential.\n\nExclusion Criteria:\n\n1. Male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for at least 3 months after the last dose of investigational product.\n2. Acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. Chronic medical conditions include human immunodeficiency virus, chronic hepatitis B virus (HBV) infection (HBV surface antigen positive), and/or hepatitis C virus infection.\n3. History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis) to any vaccine.\n4. History of microbiologically proven invasive disease caused by group B streptococcus (Streptococcus agalactiae).\n5. Previous vaccination with any licensed or investigational group B streptococcus vaccine, or planned receipt during the subject's participation in the study (through the last blood draw).","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clinical Research Atlanta","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"Kentucky Pediatric / Adult Research","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic","city":"Salt Lake City","state":"Utah","zip":"84109","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic South","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}}]},"referencesModule":{"references":[{"pmid":"32891191","type":"DERIVED","citation":"Absalon J, Segall N, Block SL, Center KJ, Scully IL, Giardina PC, Peterson J, Watson WJ, Gruber WC, Jansen KU, Peng Y, Munson S, Pavliakova D, Scott DA, Anderson AS. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect Dis. 2021 Feb;21(2):263-274. doi: 10.1016/S1473-3099(20)30478-3. Epub 2020 Sep 3."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1091001&StudyName=A+Phase+1%2C+Randomized%2C+Observer+Blinded+Trial+To+Evaluate+The+Safety%2C+Tolerability%2C+And+Immunogenicity+Of+A+Multivalent+Group+B+Streptococcus+Vaccine+In+Healthy+Adults+Aged+18+To+49+Years"},{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1091001&StudyName=A+Phase+1%2F2%2C+Randomized%2C+Placebo-controlled%2C+Observer-blinded+Trial+To+Evaluate+The+Safety%2C+Tolerability%2C+And+Immunogenicity+Of+A+Multivalent+Group+B+Streptococcus+Vaccine+In+Healthy+Adults+18+To+49+Years+Of+Age"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of Group B Streptococcus 6-valent (GBS6) vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"FG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"FG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"FG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"FG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"FG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"FG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"52"},{"groupId":"FG002","numSubjects":"52"},{"groupId":"FG003","numSubjects":"52"},{"groupId":"FG004","numSubjects":"52"},{"groupId":"FG005","numSubjects":"52"},{"groupId":"FG006","numSubjects":"52"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"52"},{"groupId":"FG002","numSubjects":"52"},{"groupId":"FG003","numSubjects":"52"},{"groupId":"FG004","numSubjects":"52"},{"groupId":"FG005","numSubjects":"52"},{"groupId":"FG006","numSubjects":"52"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"50"},{"groupId":"FG002","numSubjects":"46"},{"groupId":"FG003","numSubjects":"50"},{"groupId":"FG004","numSubjects":"51"},{"groupId":"FG005","numSubjects":"50"},{"groupId":"FG006","numSubjects":"51"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all participants who received either GBS6 vaccine or placebo.","groups":[{"id":"BG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"BG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"BG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"BG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"BG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"BG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"BG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."},{"id":"BG007","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"52"},{"groupId":"BG004","value":"52"},{"groupId":"BG005","value":"52"},{"groupId":"BG006","value":"52"},{"groupId":"BG007","value":"364"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32.9","spread":"8.43"},{"groupId":"BG001","value":"34.7","spread":"9.35"},{"groupId":"BG002","value":"32.8","spread":"8.31"},{"groupId":"BG003","value":"31.9","spread":"8.10"},{"groupId":"BG004","value":"33.2","spread":"8.67"},{"groupId":"BG005","value":"30.5","spread":"8.25"},{"groupId":"BG006","value":"32.8","spread":"8.74"},{"groupId":"BG007","value":"32.7","spread":"8.57"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"33"},{"groupId":"BG004","value":"35"},{"groupId":"BG005","value":"37"},{"groupId":"BG006","value":"43"},{"groupId":"BG007","value":"256"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"15"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"108"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"21"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"49"},{"groupId":"BG004","value":"47"},{"groupId":"BG005","value":"51"},{"groupId":"BG006","value":"47"},{"groupId":"BG007","value":"341"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"41"},{"groupId":"BG004","value":"45"},{"groupId":"BG005","value":"46"},{"groupId":"BG006","value":"44"},{"groupId":"BG007","value":"307"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"42"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"9"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"5"}]},{"title":"Native Hawaiian or other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade","description":"Hemoglobin:Grade(G)1: 11-13.5g/dL, G2:9.5-12.4g/dL,G3:8-10.4 g/dL, G4:\\<8.0 g/dL; leukocyte increase:G1: 10.8-15\\*10\\^9/Liter\\[L\\],G2:\\>15-20\\*10\\^9/L, G3:\\>20-25\\*10\\^9/L, G4:\\>25\\*10\\^9/L,leukocyte decrease: G1: 2.5-3.5\\*10\\^9/L, G2: 1.5-\\<2.5\\*10\\^9/L, G3: 1-\\<1.5\\*10\\^9/L, G4:\\<1\\*10\\^9/L; neutrophil decrease:G1: 1.5-2\\*10\\^9/L, G2:1-\\<1.5\\*10\\^9/L, G3:0.5-\\<1\\*10\\^9/L,G4:\\<0.5\\*10\\^9/L; platelets:G1: 125-140\\*10\\^9/L, G2:100-124\\*10\\^9/L, G3:25-99\\*10\\^9/L, G4:\\<25\\*10\\^9/L; eosinophils: G1: 0.65-1.5\\*10\\^9/L, G2:\\>1.5-5\\*10\\^9/L, G3:\\>5\\*10\\^9/L, G4: hypereosinophilic;alanine aminotransferase,aspartate aminotransferase:G1: 1.1-2.5 \\*ULN, G2:2.6-5.0\\*ULN, G3:5.1-10\\*ULN, G4:\\>10\\*ULN; alkaline phosphatase:G1: 1.1-2\\*ULN, G2:2.1-3\\*ULN, G3:3.1-10\\*ULN, G4:\\>10\\*ULN; Bilirubin:G1: 1.1-1.5\\*ULN, G2: 1.26-2\\*ULN,G3: 1.51-3.0\\*ULN,G4:\\>1.75\\*ULN;blood urea nitrogen:G1:23-26mg/dL,G2:27-31mg/dL,G3:\\>31mg/dL, G4:dialysis;creatinine:G1:1.5-1.7mg/dL,G2:1.8-2mg/dL,G3:2.1-2.5 mg/dL,G4:dialysis.Categories with\\>=1 participant with abnormality are reported only.","populationDescription":"Analysis population for this outcome measure included a subset of participants who received GBS6 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"1 week after vaccination","groups":[{"id":"OG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"OG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"24"}]}],"classes":[{"title":"Hemoglobin: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"12.5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.3"},{"groupId":"OG006","value":"0"}]}]},{"title":"Hemoglobin: Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Platelets: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6.3"},{"groupId":"OG003","value":"6.7"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Leukocyte decrease:Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Leukocyte increase: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.3"},{"groupId":"OG006","value":"0"}]}]},{"title":"Leukocyte increase: Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"4.2"}]}]},{"title":"Neutrophils decrease(Absolute): Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"18.8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.3"},{"groupId":"OG006","value":"0"}]}]},{"title":"Neutrophils decrease (Absolute): Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6.3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Blood urea nitrogen: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"4.2"}]}]},{"title":"Blood urea nitrogen: Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6.3"},{"groupId":"OG006","value":"0"}]}]},{"title":"Aspartate aminotransferase: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6.3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Aspartate aminotransferase: Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Alanine aminotransferase: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"12.5"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Bilirubin in presence of normal AST and ALT:Grade1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6.3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]},{"title":"Alkaline phosphate: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6.3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination","description":"Local reactions were collected by using an e-diary and included redness, swelling and pain at injection site. Redness and swelling were graded as: mild (2.5-5.0 centimeter \\[cm\\]), moderate (greater than \\[\\>\\] 5.0-10.0 cm) and severe (\\>10.0 cm), grade 4 for redness (necrosis or exfoliative dermatitis) and grade 4 for swelling (necrosis). Pain at injection site was graded as: mild (did not interfere with activity), moderate (repeated use of nonnarcotic pain reliever \\>24 hours or interfered with activity), severe (any use of narcotic pain reliever or prevented daily activity which resulted in missed days of work or school or was otherwise incapacitating, or included use of narcotics for analgesia), and grade 4 (required emergency room visit or hospitalization). The maximum severity (highest grading) of each location reaction within 14 days of vaccination was derived.","populationDescription":"Safety population included all participants who received GBS6 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Within 14 days after vaccination","groups":[{"id":"OG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"OG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"52"}]}],"classes":[{"title":"Pain:Any","categories":[{"measurements":[{"groupId":"OG000","value":"53.8","lowerLimit":"39.5","upperLimit":"67.8"},{"groupId":"OG001","value":"32.7","lowerLimit":"20.3","upperLimit":"47.1"},{"groupId":"OG002","value":"48.1","lowerLimit":"34.0","upperLimit":"62.4"},{"groupId":"OG003","value":"38.5","lowerLimit":"25.3","upperLimit":"53.0"},{"groupId":"OG004","value":"51.9","lowerLimit":"37.6","upperLimit":"66.0"},{"groupId":"OG005","value":"25.0","lowerLimit":"14.0","upperLimit":"38.9"},{"groupId":"OG006","value":"15.4","lowerLimit":"6.9","upperLimit":"28.1"}]}]},{"title":"Pain:Mild","categories":[{"measurements":[{"groupId":"OG000","value":"51.9","lowerLimit":"37.6","upperLimit":"66.0"},{"groupId":"OG001","value":"28.8","lowerLimit":"17.1","upperLimit":"43.1"},{"groupId":"OG002","value":"44.2","lowerLimit":"30.5","upperLimit":"58.7"},{"groupId":"OG003","value":"36.5","lowerLimit":"23.6","upperLimit":"51.0"},{"groupId":"OG004","value":"42.3","lowerLimit":"28.7","upperLimit":"56.8"},{"groupId":"OG005","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG006","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"}]}]},{"title":"Pain:Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG003","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG004","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG005","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG006","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"Pain:Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Pain:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Redness:Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Redness:Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Redness:Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Redness:Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Redness:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Swelling:Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG004","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Swelling:Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG004","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Swelling:Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Swelling:Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Swelling:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination","description":"Fever:38.0-38.4 degree Celsius (C),38.5-38.9 degree C,39.0-40.0 degree C,\\>40.0 degree C;nausea/vomiting:mild(not interfered with activity/1-2times in 24 hours\\[hr\\]),moderate(some interference with activity/\\>2times in 24hr),severe(prevented daily activity;required intravenous hydration); diarrhea:mild(2-3 loose stools in 24hr),moderate(4-5 loose stools in 24hr),severe(\\>=6 loose stools in 24 hr); headache:mild(not interfered with activity),moderate(repeated use of non-narcotic pain reliever \\>24 hr/some interference with activity),severe(significant;any use of narcotic pain reliever/prevented daily activity);fatigue,muscle and joint pain:mild(not interfered with activity), moderate(some interference with activity),severe(significant;prevented daily activity).Prevented daily activity=missed days of work, school/otherwise incapacitating/use of narcotics for analgesia.Nausea/vomiting,diarrhea,headache,fatigue/tiredness,muscle and joint pain: grade 4=emergency room visit or hospitalization.","populationDescription":"Safety population included all participants who received GBS6 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Within 14 days after vaccination","groups":[{"id":"OG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"OG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"52"}]}],"classes":[{"title":"Fever:>=38.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG005","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG006","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"Fever:38.0 to 38.4 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Fever:38.5 to 38.9 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"Fever:39.0 to 40.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Fever:>40.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Nausea/vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG001","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG002","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG003","value":"17.3","lowerLimit":"8.2","upperLimit":"30.3"},{"groupId":"OG004","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG005","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG006","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"}]}]},{"title":"Nausea/vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG002","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG003","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG004","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"},{"groupId":"OG005","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG006","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"}]}]},{"title":"Nausea/vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG004","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG005","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG006","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"}]}]},{"title":"Nausea/vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Nausea/vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Diarrhea:Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG001","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG002","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG003","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG004","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG005","value":"17.3","lowerLimit":"8.2","upperLimit":"30.3"},{"groupId":"OG006","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"}]}]},{"title":"Diarrhea:Mild","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG001","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG002","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG003","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG004","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG005","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG006","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"}]}]},{"title":"Diarrhea:Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG006","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"}]}]},{"title":"Diarrhea:Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG004","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Diarrhea:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Headache:Any","categories":[{"measurements":[{"groupId":"OG000","value":"40.4","lowerLimit":"27.0","upperLimit":"54.9"},{"groupId":"OG001","value":"36.5","lowerLimit":"23.6","upperLimit":"51.0"},{"groupId":"OG002","value":"32.7","lowerLimit":"20.3","upperLimit":"47.1"},{"groupId":"OG003","value":"38.5","lowerLimit":"25.3","upperLimit":"53.0"},{"groupId":"OG004","value":"40.4","lowerLimit":"27.0","upperLimit":"54.9"},{"groupId":"OG005","value":"30.8","lowerLimit":"18.7","upperLimit":"45.1"},{"groupId":"OG006","value":"42.3","lowerLimit":"28.7","upperLimit":"56.8"}]}]},{"title":"Headache:Mild","categories":[{"measurements":[{"groupId":"OG000","value":"26.9","lowerLimit":"15.6","upperLimit":"41.0"},{"groupId":"OG001","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG002","value":"15.4","lowerLimit":"6.9","upperLimit":"28.1"},{"groupId":"OG003","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG004","value":"28.8","lowerLimit":"17.1","upperLimit":"43.1"},{"groupId":"OG005","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG006","value":"23.1","lowerLimit":"12.5","upperLimit":"36.8"}]}]},{"title":"Headache:Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG001","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG002","value":"15.4","lowerLimit":"6.9","upperLimit":"28.1"},{"groupId":"OG003","value":"25.0","lowerLimit":"14.0","upperLimit":"38.9"},{"groupId":"OG004","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG005","value":"17.3","lowerLimit":"8.2","upperLimit":"30.3"},{"groupId":"OG006","value":"15.4","lowerLimit":"6.9","upperLimit":"28.1"}]}]},{"title":"Headache:Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG006","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"}]}]},{"title":"Headache:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Fatigue/tiredness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"42.3","lowerLimit":"28.7","upperLimit":"56.8"},{"groupId":"OG001","value":"32.7","lowerLimit":"20.3","upperLimit":"47.1"},{"groupId":"OG002","value":"34.6","lowerLimit":"22.0","upperLimit":"49.1"},{"groupId":"OG003","value":"26.9","lowerLimit":"15.6","upperLimit":"41.0"},{"groupId":"OG004","value":"50.0","lowerLimit":"35.8","upperLimit":"64.2"},{"groupId":"OG005","value":"38.5","lowerLimit":"25.3","upperLimit":"53.0"},{"groupId":"OG006","value":"34.6","lowerLimit":"22.0","upperLimit":"49.1"}]}]},{"title":"Fatigue/tiredness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG001","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG002","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG003","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"},{"groupId":"OG004","value":"25.0","lowerLimit":"14.0","upperLimit":"38.9"},{"groupId":"OG005","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG006","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"}]}]},{"title":"Fatigue/tiredness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"12.5","upperLimit":"36.8"},{"groupId":"OG001","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG002","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG003","value":"15.4","lowerLimit":"6.9","upperLimit":"28.1"},{"groupId":"OG004","value":"25.0","lowerLimit":"14.0","upperLimit":"38.9"},{"groupId":"OG005","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG006","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"}]}]},{"title":"Fatigue/tiredness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG003","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"}]}]},{"title":"Fatigue/tiredness:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Muscle pain:Any","categories":[{"measurements":[{"groupId":"OG000","value":"17.3","lowerLimit":"8.2","upperLimit":"30.3"},{"groupId":"OG001","value":"25.0","lowerLimit":"14.0","upperLimit":"38.9"},{"groupId":"OG002","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG003","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG004","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG005","value":"23.1","lowerLimit":"12.5","upperLimit":"36.8"},{"groupId":"OG006","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"}]}]},{"title":"Muscle pain:Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG001","value":"17.3","lowerLimit":"8.2","upperLimit":"30.3"},{"groupId":"OG002","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"},{"groupId":"OG003","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG004","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG005","value":"17.3","lowerLimit":"8.2","upperLimit":"30.3"},{"groupId":"OG006","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"}]}]},{"title":"Muscle pain:Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"},{"groupId":"OG001","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"},{"groupId":"OG002","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG003","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"},{"groupId":"OG004","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG005","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG006","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"}]}]},{"title":"Muscle pain:Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0.0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"Muscle pain:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Joint pain:Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG001","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG002","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG003","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG004","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG005","value":"11.5","lowerLimit":"4.4","upperLimit":"23.4"},{"groupId":"OG006","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"}]}]},{"title":"Joint pain:Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG001","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG003","value":"7.7","lowerLimit":"2.1","upperLimit":"18.5"},{"groupId":"OG004","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG005","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG006","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"Joint pain:Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG001","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG002","value":"9.6","lowerLimit":"3.2","upperLimit":"21.0"},{"groupId":"OG003","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG004","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"},{"groupId":"OG005","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG006","value":"3.8","lowerLimit":"0.5","upperLimit":"13.2"}]}]},{"title":"Joint pain:Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]},{"title":"Joint pain:Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. AEs included both non-serious AEs and SAEs.","populationDescription":"Safety population included all participants who received GBS6 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Within 1 month after vaccination","groups":[{"id":"OG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"OG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"52"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG001","value":"5.8","lowerLimit":"1.2","upperLimit":"15.9"},{"groupId":"OG002","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG003","value":"13.5","lowerLimit":"5.6","upperLimit":"25.8"},{"groupId":"OG004","value":"26.9","lowerLimit":"15.6","upperLimit":"41.0"},{"groupId":"OG005","value":"28.8","lowerLimit":"17.1","upperLimit":"43.1"},{"groupId":"OG006","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.","populationDescription":"Safety population included all participants who received GBS6 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Within 6 months after vaccination","groups":[{"id":"OG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"OG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"52"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG002","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG004","value":"1.9","lowerLimit":"0.0","upperLimit":"10.3"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"6.8"},{"groupId":"OG006","value":"0","lowerLimit":"0.0","upperLimit":"6.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination","description":"An AE was any untoward medical occurrence in a participant in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.","populationDescription":"Safety population included all participants who received GBS6 vaccine or placebo.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Within 6 months after vaccination","groups":[{"id":"OG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"OG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"52"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","lowerLimit":"11.1","upperLimit":"34.7"},{"groupId":"OG001","value":"23.1","lowerLimit":"12.5","upperLimit":"36.8"},{"groupId":"OG002","value":"28.8","lowerLimit":"17.1","upperLimit":"43.1"},{"groupId":"OG003","value":"19.2","lowerLimit":"9.6","upperLimit":"32.5"},{"groupId":"OG004","value":"34.6","lowerLimit":"22.0","upperLimit":"49.1"},{"groupId":"OG005","value":"26.9","lowerLimit":"15.6","upperLimit":"41.0"},{"groupId":"OG006","value":"34.6","lowerLimit":"22.0","upperLimit":"49.1"}]}]}]},{"type":"SECONDARY","title":"GBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination","description":"Serotypes used for evaluation were: Ia, Ib, II, III, IV, and V.","populationDescription":"Evaluable immunogenicity population included all eligible participants who received GBS6 vaccine or placebo, had 1 month after vaccination blood drawn for assay and had at least 1 valid determinate assay result with no major protocol violation. 'Number analyzed' = number of participants with valid, determinate assay results for specified serotype.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Microgram per milliliter","timeFrame":"1 month after vaccination","groups":[{"id":"OG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months"},{"id":"OG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months."},{"id":"OG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"47"}]}],"classes":[{"title":"Ia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.880","lowerLimit":"13.301","upperLimit":"71.691"},{"groupId":"OG001","value":"20.341","lowerLimit":"8.533","upperLimit":"48.486"},{"groupId":"OG002","value":"24.723","lowerLimit":"10.577","upperLimit":"57.785"},{"groupId":"OG003","value":"41.826","lowerLimit":"17.740","upperLimit":"98.613"},{"groupId":"OG004","value":"21.125","lowerLimit":"10.121","upperLimit":"44.094"},{"groupId":"OG005","value":"17.829","lowerLimit":"7.542","upperLimit":"42.149"},{"groupId":"OG006","value":"0.755","lowerLimit":"0.372","upperLimit":"1.536"}]}]},{"title":"Ib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"49"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.060","lowerLimit":"0.891","upperLimit":"4.762"},{"groupId":"OG001","value":"2.051","lowerLimit":"0.952","upperLimit":"4.417"},{"groupId":"OG002","value":"3.174","lowerLimit":"1.368","upperLimit":"7.365"},{"groupId":"OG003","value":"3.639","lowerLimit":"1.426","upperLimit":"9.289"},{"groupId":"OG004","value":"2.742","lowerLimit":"1.102","upperLimit":"6.820"},{"groupId":"OG005","value":"1.948","lowerLimit":"0.785","upperLimit":"4.836"},{"groupId":"OG006","value":"0.034","lowerLimit":"0.019","upperLimit":"0.059"}]}]},{"title":"II","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.851","lowerLimit":"17.303","upperLimit":"58.630"},{"groupId":"OG001","value":"21.919","lowerLimit":"11.544","upperLimit":"41.618"},{"groupId":"OG002","value":"26.980","lowerLimit":"14.586","upperLimit":"49.904"},{"groupId":"OG003","value":"57.011","lowerLimit":"31.917","upperLimit":"101.832"},{"groupId":"OG004","value":"37.258","lowerLimit":"20.764","upperLimit":"66.853"},{"groupId":"OG005","value":"31.786","lowerLimit":"17.490","upperLimit":"57.770"},{"groupId":"OG006","value":"0.187","lowerLimit":"0.126","upperLimit":"0.279"}]}]},{"title":"III","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"49"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.683","lowerLimit":"3.002","upperLimit":"10.760"},{"groupId":"OG001","value":"4.531","lowerLimit":"2.290","upperLimit":"8.965"},{"groupId":"OG002","value":"4.979","lowerLimit":"2.346","upperLimit":"10.571"},{"groupId":"OG003","value":"12.806","lowerLimit":"6.221","upperLimit":"26.365"},{"groupId":"OG004","value":"5.559","lowerLimit":"2.724","upperLimit":"11.345"},{"groupId":"OG005","value":"3.766","lowerLimit":"1.887","upperLimit":"7.517"},{"groupId":"OG006","value":"0.081","lowerLimit":"0.054","upperLimit":"0.122"}]}]},{"title":"IV","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.915","lowerLimit":"1.712","upperLimit":"4.964"},{"groupId":"OG001","value":"5.149","lowerLimit":"2.913","upperLimit":"9.102"},{"groupId":"OG002","value":"4.924","lowerLimit":"3.077","upperLimit":"7.879"},{"groupId":"OG003","value":"4.908","lowerLimit":"2.890","upperLimit":"8.336"},{"groupId":"OG004","value":"4.303","lowerLimit":"2.605","upperLimit":"7.107"},{"groupId":"OG005","value":"7.018","lowerLimit":"4.518","upperLimit":"10.903"},{"groupId":"OG006","value":"0.046","lowerLimit":"0.027","upperLimit":"0.078"}]}]},{"title":"V","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"52"},{"groupId":"OG005","value":"52"},{"groupId":"OG006","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.985","lowerLimit":"1.346","upperLimit":"6.619"},{"groupId":"OG001","value":"3.368","lowerLimit":"1.477","upperLimit":"7.679"},{"groupId":"OG002","value":"4.702","lowerLimit":"2.033","upperLimit":"10.878"},{"groupId":"OG003","value":"5.142","lowerLimit":"2.403","upperLimit":"11.005"},{"groupId":"OG004","value":"3.991","lowerLimit":"1.984","upperLimit":"8.031"},{"groupId":"OG005","value":"6.760","lowerLimit":"3.230","upperLimit":"14.146"},{"groupId":"OG006","value":"0.143","lowerLimit":"0.084","upperLimit":"0.244"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Local reactions and systemic events: within 14 days after vaccination on Day 1 and all AEs other than local reactions and systemic events: within 6 Months after vaccination on Day 1","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.Safety population included all participants who received GBS6 vaccine or placebo.","eventGroups":[{"id":"EG000","title":"GBS6 5 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":1,"seriousNumAtRisk":52,"otherNumAffected":40,"otherNumAtRisk":52},{"id":"EG001","title":"GBS6 5 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 5 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":35,"otherNumAtRisk":52},{"id":"EG002","title":"GBS6 10 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months.","deathsNumAffected":1,"deathsNumAtRisk":52,"seriousNumAffected":1,"seriousNumAtRisk":52,"otherNumAffected":39,"otherNumAtRisk":52},{"id":"EG003","title":"GBS6 10 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 10 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":36,"otherNumAtRisk":52},{"id":"EG004","title":"GBS6 20 Microgram With Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine with aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":1,"seriousNumAtRisk":52,"otherNumAffected":41,"otherNumAtRisk":52},{"id":"EG005","title":"GBS6 20 Microgram Without Aluminum Phosphate","description":"Participants were randomized to receive a single dose of 20 microgram of GBS6 vaccine without aluminium phosphate, intramuscularly on Day 1 and were followed up to 6 months.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":36,"otherNumAtRisk":52},{"id":"EG006","title":"Placebo","description":"Participants were randomized to receive placebo (saline control) intramuscularly on Day 1 and were followed up to 6 months.","deathsNumAffected":0,"deathsNumAtRisk":52,"seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":35,"otherNumAtRisk":52}],"seriousEvents":[{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":52},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":0,"numAtRisk":52}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":52},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":0,"numAtRisk":52}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":52},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":1,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":0,"numAtRisk":52}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":52},{"groupId":"EG001","numAffected":11,"numAtRisk":52},{"groupId":"EG002","numAffected":7,"numAtRisk":52},{"groupId":"EG003","numAffected":11,"numAtRisk":52},{"groupId":"EG004","numAffected":11,"numAtRisk":52},{"groupId":"EG005","numAffected":9,"numAtRisk":52},{"groupId":"EG006","numAffected":6,"numAtRisk":52}]},{"term":"Nausea/vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":52},{"groupId":"EG002","numAffected":6,"numAtRisk":52},{"groupId":"EG003","numAffected":9,"numAtRisk":52},{"groupId":"EG004","numAffected":5,"numAtRisk":52},{"groupId":"EG005","numAffected":6,"numAtRisk":52},{"groupId":"EG006","numAffected":11,"numAtRisk":52}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":52},{"groupId":"EG001","numAffected":17,"numAtRisk":52},{"groupId":"EG002","numAffected":18,"numAtRisk":52},{"groupId":"EG003","numAffected":14,"numAtRisk":52},{"groupId":"EG004","numAffected":26,"numAtRisk":52},{"groupId":"EG005","numAffected":20,"numAtRisk":52},{"groupId":"EG006","numAffected":18,"numAtRisk":52}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":2,"numAtRisk":52},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":3,"numAtRisk":52}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":2,"numAtRisk":52},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":1,"numAtRisk":52},{"groupId":"EG005","numAffected":3,"numAtRisk":52},{"groupId":"EG006","numAffected":2,"numAtRisk":52}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":52},{"groupId":"EG002","numAffected":2,"numAtRisk":52},{"groupId":"EG003","numAffected":1,"numAtRisk":52},{"groupId":"EG004","numAffected":2,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":2,"numAtRisk":52}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":3,"numAtRisk":52},{"groupId":"EG003","numAffected":1,"numAtRisk":52},{"groupId":"EG004","numAffected":4,"numAtRisk":52},{"groupId":"EG005","numAffected":6,"numAtRisk":52},{"groupId":"EG006","numAffected":3,"numAtRisk":52}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":0,"numAtRisk":52},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":1,"numAtRisk":52},{"groupId":"EG005","numAffected":3,"numAtRisk":52},{"groupId":"EG006","numAffected":0,"numAtRisk":52}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":52},{"groupId":"EG001","numAffected":5,"numAtRisk":52},{"groupId":"EG002","numAffected":7,"numAtRisk":52},{"groupId":"EG003","numAffected":5,"numAtRisk":52},{"groupId":"EG004","numAffected":7,"numAtRisk":52},{"groupId":"EG005","numAffected":6,"numAtRisk":52},{"groupId":"EG006","numAffected":3,"numAtRisk":52}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":52},{"groupId":"EG001","numAffected":13,"numAtRisk":52},{"groupId":"EG002","numAffected":10,"numAtRisk":52},{"groupId":"EG003","numAffected":10,"numAtRisk":52},{"groupId":"EG004","numAffected":10,"numAtRisk":52},{"groupId":"EG005","numAffected":12,"numAtRisk":52},{"groupId":"EG006","numAffected":10,"numAtRisk":52}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":52},{"groupId":"EG001","numAffected":19,"numAtRisk":52},{"groupId":"EG002","numAffected":17,"numAtRisk":52},{"groupId":"EG003","numAffected":20,"numAtRisk":52},{"groupId":"EG004","numAffected":21,"numAtRisk":52},{"groupId":"EG005","numAffected":16,"numAtRisk":52},{"groupId":"EG006","numAffected":22,"numAtRisk":52}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":0,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":52},{"groupId":"EG003","numAffected":1,"numAtRisk":52},{"groupId":"EG004","numAffected":0,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":3,"numAtRisk":52}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":52},{"groupId":"EG001","numAffected":17,"numAtRisk":52},{"groupId":"EG002","numAffected":25,"numAtRisk":52},{"groupId":"EG003","numAffected":20,"numAtRisk":52},{"groupId":"EG004","numAffected":27,"numAtRisk":52},{"groupId":"EG005","numAffected":13,"numAtRisk":52},{"groupId":"EG006","numAffected":8,"numAtRisk":52}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":3,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":52},{"groupId":"EG003","numAffected":2,"numAtRisk":52},{"groupId":"EG004","numAffected":3,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":0,"numAtRisk":52}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA v 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":52},{"groupId":"EG001","numAffected":2,"numAtRisk":52},{"groupId":"EG002","numAffected":1,"numAtRisk":52},{"groupId":"EG003","numAffected":0,"numAtRisk":52},{"groupId":"EG004","numAffected":3,"numAtRisk":52},{"groupId":"EG005","numAffected":0,"numAtRisk":52},{"groupId":"EG006","numAffected":0,"numAtRisk":52}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-08-29","uploadDate":"2019-06-13T10:37","filename":"Prot_000.pdf","size":774929},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-02-07","uploadDate":"2019-06-13T10:37","filename":"SAP_001.pdf","size":421494}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D013290","term":"Streptococcal Infections"}],"ancestors":[{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}